vatalanib has been researched along with rtki cpd in 2 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (rtki cpd) | Trials (rtki cpd) | Recent Studies (post-2010) (rtki cpd) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 41 | 0 | 21 |
| 276 | 42 | 98 | 744 | 0 | 257 |
| Protein | Taxonomy | vatalanib (IC50) | rtki cpd (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.125 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1152 | |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | 1.3 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 2.7 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.56 | |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | 0.125 | |
| Epidermal growth factor receptor | Mus musculus (house mouse) | 0.1 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.56 | |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 0.53 | |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | 1.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K | 1 |
| Bondesson, M; Hans, C; Harris, PS; Hemmer, MJ; Kleinstreuer, N; Knudsen, TB; McCollum, CW; Merchant, FA; Olin, J; Padilla, S; Shah, S; Tal, TL; Wood, CE | 1 |
2 other study(ies) available for vatalanib and rtki cpd
| Article | Year |
|---|---|
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
Immediate and long-term consequences of vascular toxicity during zebrafish development.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Blood Vessels; Embryo, Nonmammalian; Embryonic Development; ErbB Receptors; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2014 |